trending Market Intelligence /marketintelligence/en/news-insights/trending/KJaXzXkj6oKIIVuT7Xn6Sw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Axsome Therapeutics raises $23.3M from stock offering to fund drug programs

Axsome Therapeutics Inc. raised about $23.3 million from a stock offering carried out with Leerink Partners LLC.

The New York-based biopharmaceutical company sold 2,881,066 shares in the offering.

Axsome intends to use the proceeds to fund the ongoing clinical development of its late-stage product candidates and for other general corporate purposes.

Just recently, the company, which develops therapies for managing central nervous system disorders, reported positive data from a mid-stage study, which showed that its medicine AXS-05 helped reduce depression symptoms in patients.